JPET Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 29, 2004; DOI: 10.1124/jpet.104.068890


0022-3565/04/3112-625-633$20.00
JPET 311:625-633, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.068890v1
311/2/625    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCluskie, K.
Right arrow Articles by Belvisi, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCluskie, K.
Right arrow Articles by Belvisi, M. G.

INFLAMMATION AND IMMUNOPHARMACOLOGY

Nitric Oxide as a Noninvasive Biomarker of Lipopolysaccharide-Induced Airway Inflammation: Possible Role in Lung Neutrophilia

Kerryn McCluskie, Mark A. Birrell, Sissie Wong, and Maria G. Belvisi

Respiratory Pharmacology, Imperial College London, Faculty of Medicine, National Heart and Lung Institute, London, United Kingdom

Lipopolysaccharide (LPS) is known to generate nitric oxide (NO) in the airway through the activation of nitric-oxide synthase (NOS). The functional consequences of this on the inflammatory response are not clear, with conflicting data published. In the clinic, exhaled NO (ex-NO) is used as a noninvasive biomarker to assess the extent of airway inflammation. It is proposed that monitoring levels of ex-NO could be a useful guide to determining the effectiveness of disease modifying therapies. The aim was, using pharmacological tools, to determine the role of NO in an aerosolized LPS-driven animal model of airway inflammation by assessment of ex-NO, neutrophilia, and inflammatory biomarkers, using a nonselective NOS inhibitor, NG-nitro-L-arginine methyl ester (L-NAME), and a selective inducible NOS (iNOS) inhibitor, N-3 (aminomethyl)benzyl)acetamidine (1400W). Real-time mRNA analysis of the lung tissue indicated an increased gene expression of iNOS following LPS challenge with minimal impact on constitutive NOS isoforms. LPS induced an increase in ex-NO, which appeared to correlate with the increase in iNOS gene expression and airway neutrophilia. Treatment with L-NAME and 1400W resulted in comparable reductions in ex-NO, a reduction in airway neutrophilia, but had little impact on a range of inflammatory biomarkers. This study indicates that the LPS-induced rise in ex-NO is due to enhanced iNOS activity and that NO has a role in airway neutrophilia. Additionally, it appears using ex-NO as a guide to monitoring airway inflammation may have some use, but data should be interpreted with caution when assessing therapies that may directly impact on NO formation.


Received March 25, 2004; accepted June 29, 2004.

Address correspondence to: Maria G. Belvisi, Head Respiratory Pharmacology Group, Imperial College London, Faculty of Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK. E-mail: m.belvisi{at}imperial.ac.uk




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. A. Birrell, M. C. Catley, E. Hardaker, S. Wong, T. M. Willson, K. McCluskie, T. Leonard, S. N. Farrow, J. L. Collins, S. Haj-Yahia, et al.
Novel Role for the Liver X Nuclear Receptor in the Suppression of Lung Inflammatory Responses
J. Biol. Chem., November 2, 2007; 282(44): 31882 - 31890.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. A. Birrell, K. McCluskie, E. Hardaker, R. Knowles, and M. G. Belvisi
Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model
Eur. Respir. J., December 1, 2006; 28(6): 1236 - 1244.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. McCluskie, U. Klein, C. Linnevers, Y.-h. Ji, A. Yang, C. Husfeld, and G. R. Thomas
Phosphodiesterase Type 4 Inhibitors Cause Proinflammatory Effects in Vivo
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 468 - 476.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
C. M. Prado, E. A. Leick-Maldonado, L. Yano, A. S. Leme, V. L. Capelozzi, M. A. Martins, and I. F. L. C. Tiberio
Effects of Nitric Oxide Synthases in Chronic Allergic Airway Inflammation and Remodeling
Am. J. Respir. Cell Mol. Biol., October 1, 2006; 35(4): 457 - 465.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. A. Birrell, S. Wong, A. Dekkak, J. De Alba, S. Haj-Yahia, and M. G. Belvisi
Role of Matrix Metalloproteinases in the Inflammatory Response in Human Airway Cell-Based Assays and in Rodent Models of Airway Disease
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 741 - 750.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. A. Birrell, S. Wong, D. J. Hele, K. McCluskie, E. Hardaker, and M. G. Belvisi
Steroid-resistant Inflammation in a Rat Model of Chronic Obstructive Pulmonary Disease Is Associated with a Lack of Nuclear Factor-{kappa}B Pathway Activation
Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 74 - 84.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.